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Summary
Objective: This long-term event monitoring (LEM) study was designed to evaluate the long-
term lipid-lowering efﬁcacy and safety of ﬂuvastatin (Lochol®, Novartis A.G.) along with the
incidence of cardiac and other events, and safety of ﬂuvastatin in Japanese patients withLocal event
monitoring;
Safety
hypercholesterolemia.
Methods: Patients (n = 21,139) who started ﬂuvastatin between April 1, 2000 and March 31,
2002, across 2563 centers in Japan were prospectively registered and followed up for 3 years
(secondary prevention cohort) or 5 years (primary prevention cohort).
Results: Of the patients registered, 19,084 were included in this analysis. Levels of low-density
lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) decreased signiﬁcantly in the primary
(−27.1% and −18.8%) and secondary (−25.3% and −18.4%) prevention cohorts. Reductions
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in LDL-C (−22.1 vs. −18.2%, p < 0.0001) and TC (−16.1 vs. −13.1%, p < 0.0001) levels were signif-
icantly greater among patients aged ≥65 than <65 years old. Overall, 1.7% (146/8563) and 1.1%
(93/8563) of patients aged ≥65 years old experienced conﬁrmed cardiac and cerebral events,
compared with 1.1% (112/10,517) and 0.3% (28/10,517) of patients aged <65 years old (p = 0.0002
and <0.0001, respectively). Incidence of cardiac and cerebral events was lowest in patients aged
<65 years old in the primary prevention cohort and highest among patients aged ≥65 years old
in the secondary prevention cohort. Adverse events were reported in 7.9% (1501/19,084) of
patients.
Conclusion: This large-scale, prospective, uncontrolled study conﬁrmed the lipid-lowering efﬁ-
cacy and safety of long-term ﬂuvastatin treatment for hypercholesterolemia in Japanese patients
aged ≥65 years old. The higher incidence of cardiac and cerebral events in patients aged ≥65
years old in the secondary prevention cohort reﬂects a high-risk clinical proﬁle with multiple
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Patients were initially registered between April 1,classic risk factors warrantin
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luvastatin (Lochol®, Novartis A.G.), introduced in 1983,
as the ﬁrst chemically synthesized 3-hydroxy-3-methyl-
lutaryl (HMG)-CoA reductase inhibitor for the treatment
f hypercholesterolemia. Unlike prior HMG-CoA reductase
nhibitors that were derived from microbial metabolites,
uvastatin contains an indole ring as its basic chemical struc-
ure and its side chain contains a heptene residue that is
imilar in chemical structure to HMG-CoA, the endogenous
ubstrate of HMG-CoA reductase.
Statin-type drugs (HMG-CoA reductase inhibitors) are
enerally well tolerated with a low incidence of poten-
ially serious side effects. In particular, large-scale clinical
rials such as the 4S (Scandinavian Simvastatin Survival
tudy) [1], WOSCOPS (West of Scotland Coronary Preven-
ion Study) Group [2], and CARE (Cholesterol And Recurrent
vents) Trial [3], trials conducted in Europe/North Amer-
ca, and the J-LIT (Japan Lipid Intervention Trial) [4] and
EGA Study [5] in Japan have demonstrated the safety of
ong-term administration of natural statins (fermentation-
erived statins), including pravastatin and simvastatin.
ince relatively short-term (24—52 weeks) studies are con-
ucted for drug approval, long-term cohort studies are an
mportant facet of drug development and can demonstrate
he long-term efﬁcacy and safety of a drug.
We conducted a long-term cohort study using long-term
vent monitoring (LEM) to evaluate the efﬁcacy and safety of
uvastatin in Japanese patients with hypercholesterolemia
n everyday clinical practice, focusing on primary and sec-
ndary prevention cohorts (patients without or with prior
istory of cardiac/cerebral events). In addition, because
large number of patients with hypercholesterolemia are
ged ≥65 years old, a range in which the incidence of
ardiac and cerebral events is relatively high, we also
ocused on the safety and efﬁcacy of ﬂuvastatin for patients
ged ≥65 years old and compared to those <65 years
ld.
ethodsubjects
atients with hypercholesterolemia or familial hyperc-
olesterolemia who had not received therapy for hyper-
2
p
a
t
altifactorial interventions.
ology. Published by Elsevier Ltd. All rights reserved.
holesterolemia for 4 weeks and who started ﬂuvastatin
ere eligible for this study. Patients who received any
ipid-lowering therapy in the 4 weeks prior to receiving
uvastatin were excluded from this analysis. Patients who
ad previously used ﬂuvastatin, including the 4 weeks prior
o this study, were excluded, as were secondary cases
ther than hypercholesterolemia or familial hypercholes-
erolemia.
egistry protocol
ll patients were registered using a central registry method.
vent monitoring was conducted under everyday clinical
se, and case report forms (CRFs) were completed by the
hysicians every 6 months and transferred to the central
egistry. The investigators explained the objective of the
tudy to their patients requesting participation in this study.
nformed consent was obtained from each patient prior to
he registration.
The regular event monitoring of the patients was con-
ucted at 6-month interval for up to 5 years or 3 years
or patients with a history of coronary artery diseases
CADs) or complications of CAD. At each visit (and between
isits as necessary), the physicians recorded details of
ny events, including cerebral, cardiac, and other adverse
vents, and the time of the events, in addition to demo-
raphic characteristics, concomitant medications, drug
ompliance, blood pressure, body weight, serum parameters
low-density lipoprotein-cholesterol [LDL-C], high-density
ipoprotein-cholesterol [HDL-C], total cholesterol [TC],
riglycerides [TG], creatinine kinase [CK], CK-myocardial
and [Mb], aspartate transferase [AST], lactate dehydro-
enase [LDH] and white blood cell count [WBC]), lifestyle
actors (dietary/exercise guidance; alcohol intake, and
moking status) and performed electrocardiography (ECG).
ll data were recorded in case report forms. Adverse
rug reactions were deﬁned as adverse events for which
causal relationship with the study drug could not be000 and March 31, 2002; the study follow-up was com-
leted on March 31, 2007. This study was conducted in
ccordance with Good Post-marketing Surveillance Prac-
ice regulations [6]. Institutional Review Board (IRB)
pproval was obtained at all sites with an established
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IRB. Written informed consent was obtained from all
patients.
Treatments
All patients included in the registry were given ﬂuvastatin,
once daily after dinner. The initial dosage was 20mg; which
could be increased to 60mg/day, to achieve the appropri-
ate LDL-C level recommended by the dyslipidemia guidelines
published by the Japan Atherosclerosis Society [7], [LDL-C
to <140mg/dL in patients without CAD or risk factors (≥45
years old for males, post-menopausal for women; family
history of CAD; smoking; hypertension, systolic blood pres-
sure ≥140mmHg and/or diastolic blood pressure ≥90mmHg;
obesity, body mass index (BMI) ≥26.4 kg/m2 (≥25.0 kg/m2
from 2005); impaired glucose tolerance according to Japan
Diabetes Society criteria [8]; hypertriglyceridemia, low HDL
cholesterolemia, arteriosclerotic disease other than CAD);
to <120mg/dL in patients without CAD but with any of
these risk factors; and to <100mg/dL in patients with CAD,
irrespective of other risk factors]. The study protocol did
not provide any guidance on the use of antiplatelet drugs,
cholesterol-lowering drugs, or other concomitant therapies,
other than to continue standard therapy. Therefore, the use
of concomitant therapies was at the discretion of each inves-
tigator.
Deﬁnitions and endpoints
Cardiac and cerebral events were reviewed by an Event
Evaluation Committee (EEC). For cardiac events, the EEC
reviewed the following parameters: ECG ﬁndings, clini-
cal symptoms, biochemistry parameters (CK, CK-Mb, AST,
LDH, and WBC), medical course, complications, outcomes,
and any comments recorded by the chief physician. Car-
diac events were deﬁned as fatal/non-fatal myocardial
infarction (MI), cardiac death, angina pectoris, or asymp-
tomatic myocardial ischemia. Cerebrovascular events were
also reviewed by EEC members, based on computed
tomography/magnetic resonance imaging ﬁndings, clini-
cal symptoms, biochemistry parameters, medical course,
complications (atrial ﬁbrillation, MI), outcomes, and any
comments recorded by the chief physician. Cerebrovascular
events were deﬁned as cerebral infarction (cerebral throm-
bosis or cerebral embolism), intracranial hemorrhage, sub-
arachnoid hemorrhage, and transient ischemic attack (TIA).
All cerebrovascular and cardiac events were assessed based
on standard diagnostic criteria (Supplementary Table 1).
The primary endpoint was the incidence of cardiac events
and cerebral events during long-term treatment with ﬂu-
vastatin. Secondary endpoints included the type, severity,
and incidence of side effects other than the above events
during long-term use of the drug. Secondary endpoints also
included changes in serum lipid parameters.
As described above, patients were included in the pri-
mary prevention group or in the secondary prevention group
if they had prior history of cardiac (e.g. coronary arterial
disease) or cerebral (e.g. cerebral infarction and cerebral
hemorrhage) events. The presence or absence of prior car-
diac or cerebral events was determined on a case-by-case
basis by members of the Advisory Board. The secondary
t
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revention cohorts were also stratiﬁed according to prior
istory of cardiac or cerebral events.
LDL-C values were calculated using Friedewald’s for-
ula. LDL-C was not calculated for subjects with a TG value
400mg/dL. However, if LDL-C was measured using a direct
ethod, this value was used instead.
tatistical analysis
ll data were analyzed for the full study population, and
fter stratiﬁcation into the primary/secondary prevention
ohorts and according to age <65/≥65 years old. Patients
ith only baseline data were excluded from efﬁcacy and
afety analyses. The incidence of cardiac and cerebral
vents was estimated using the Kaplan—Meier method fol-
owed by log-rank tests to compare groups. The associations
etween the incidence, LDL-C levels, and other risk fac-
ors (hypertension, glucose intolerance, obesity, age, sex,
nd smoking) before and after administration of the drug
ere also evaluated using the Cox proportional hazards
odel.
esults
atient characteristics
total of 21,139 patients were initially registered in this
tudy. CRFs were collected for 19,105 patients at the start
f the study (Supplementary Table 2 and Supplementary
ig. 1). Twenty-one patients were subsequently excluded
y the Advisory Board and the safety evaluation set com-
rised 19,084 patients. Of these, follow-up data were
ollected for 13,005 (68.2%) patients at 1 year, 10,391
54.5%) at 2 years, 8830 (46.3%) at 3 years, 6851 (39.9%)
t 4 years and 6175 (35.9%) at 5 years. During years 1—5,
1, 51, 56, 34, and 29 patients died, respectively. Overall,
165 (42.8%) patients discontinued from the study dur-
ng the study period at the patient’s request or because
f their circumstances (e.g. patient was lost to follow-
p/did not attend the visit; transfer to another department
r hospital). Meanwhile, 1568 (8.2%) patients discontin-
ed either because of no improvement in lipid levels, or
ecause of the improvement in lipid levels meant lipid-
owering therapy was no longer deemed necessary by the
hysician. Furthermore, 779 (4.1%) patients discontinued
ecause of adverse events, and 239 (1.3%) discontinued
or another reason (e.g. hospitalization, changes in attend-
ng physician’s situation). Of the 19,084 eligible patients,
000 were excluded for the following reasons (3 patients
et multiple exclusion criteria): 940 patients with initial
C <220mg/dL (TC within the normal range), 60 patients
ith an unknown/unclear therapeutic category according
o the Japan Atherosclerosis Society criteria and could not
e assigned to the primary or secondary cohorts, and 3
atients received ﬂuvastatin in an off-label manner. Thus,
he efﬁcacy evaluation set comprised 18,084 patients. The
rimary and secondary prevention cohorts comprised 17,189
90.0%) and 1895 (9.9%), respectively. The mean dose of
uvastatin in the total cohort was 21.3mg/day at study
tart.
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Table 1 Baseline characteristics.
Total population Prevention cohort Age groupsa
Primary Secondary <65 years ≥65 years
N 19,084 17,189 1895 10,517 8563
Male 5615 (29.4) 4716 (27.4) 899 (47.4)b 3505 (33.3) 2110 (24.6)d
Female 13,469 (70.6) 12,473 (72.6) 996 (52.6)b 7012 (66.7) 6453 (75.4)d
Post menopause 12,126 (90.0) 11,164 (89.5) 962 (96.6)b 5669 (80.9) 6453 (100.0)d
Age (years) 62.3± 11.1 61.8± 11.0 67.2± 10.3 54.4± 7.6 72.1± 5.5
<65 years 10,517 (55.1) 9818 (57.1) 699 (36.9)b 10,517 (100.0) 0
≥65 years 8563 (44.9) 7367 (42.9) 1196 (63.1)b 0 8563 (100.0)
BMI
<25 kg/m2 10,139 (53.1) 9118 (53.1) 1021 (53.9) 5412 (51.5) 4725 (55.2)d
≥25 kg/m2 4916 (25.8) 4392 (25.6) 524 (27.7) 3010 (28.6) 1905 (22.3)d
Blood pressure (mmHg)
Diastolic 78.6± 10.8 78.8± 10.8 77.1± 11.1 79.6± 11.2 77.5± 10.3e
Systolic 135.4± 17.9 135.4± 17.8 135.6± 18.2c 133.3± 17.9 137.9± 17.5e
Family history of CAD 690 (3.6) 481 (2.8) 209 (11.0)b 416 (4.0) 274 (3.2)
Smoking 2517 (13.2) 2216 (12.9) 301 (15.9)b 1839 (17.5) 678 (7.9)d
Hypercholesterolemia 18,966 (99.4) 17,078 (99.4) 1888 (99.6) 10,423 (99.1) 8539 (99.7)
Familial hypercholesterolemia 118 (0.6) 111 (0.7) 7 (0.4) 94 (0.9) 24 (0.3)d
WHO class
II a 10,844 (56.8) 9483 (57.6) 1001 (53.0)b 5739 (55.1) 5103 (59.8)
II b 7595 (40.1) 6762 (39.6) 833 (44.0) 4391 (42.1) 3202 (37.5)
Other (I) 15 (0.1) 14 (0.1) 1 (0.1) 9 (0.1) 6 (0.1)
Other (III) 50 (0.3) 43 (0.3) 7 (0.4) 33 (0.3) 17 (0.2)
Other (IV) 65 (0.3) 52 (0.3) 13 (0.7) 34 (0.3) 31 (0.4)
Other (V) 16 (0.1) 12 (0.1) 4 (0.2) 13 (0.1) 3 (<0.1)
Other (secondary) 2 (<0.1) 2 (<0.1) 0 2 (<0.1) 0 (0.0)
Pretreatment with lipid-lowering therapy 249 (1.3) 215 (1.3) 34 (1.8) 117 (1.1) 132 (1.5)
Complications 14,459 (75.8) 12,577 (73.2) 1882 (99.3) 7268 (69.1) 7188 (83.9)d
Hypertension 8855 (46.4) 7723 (44.9) 1132 (59.7) 4044 (38.5) 4809 (56.2)d
Diabetes/impaired glucose tolerance 3325 (17.4) 2847 (16.6) 478 (25.2) 1760 (16.7) 1565 (18.3)d
Cardiac disease 3056 (16.0) 1249 (7.3) 1807 (95.4) 1141 (10.9) 1914 (22.4)d
Liver disorders 1169 (6.1) 1071 (6.2) 98 (5.2) 831 (7.9) 338 (4.0)d
Kidney disorders 502 (2.6) 422 (2.5) 80 (4.2)b 253 (2.4) 248 (2.9)
Cerebrovascular disorders 1222 (6.4) 1060 (6.2) 162 (8.6)b 364 (3.5) 858 (10.0)
ECG abnormalities 2314 (12.1) 1466 (8.5) 848 (44.8)b 967 (20.9) 1347 (31.4)d
Lipid parameters (mg/dL)
TC 261.8± 27.8 263.0± 27.5 250.9± 28.0c 264.4± 28.8 258.6± 26.1e
HDL-C 59.6± 16.6 60.1± 16.6 55.3± 15.8c 59.7± 16.8 59.5± 16.2
LDL-C 171.3± 27.8 172.2± 27.7 163.5± 27.3c 173.0± 28.8 169.2± 26.4e
TG 166.2± 122.7 165.6± 122.8 171.8± 121.5c 175.6± 145.2 154.6± 86.2e
Fluvastatin dose (mg/day)
Study start 21.3± 4.5 21.3± 4.5 21.6± 4.8 21.4± 4.6 21.3± 4.5
Study end 22.7± 6.7 22.6± 6.7 23.2± 7.3 22.9± 6.2 22.3± 6.2
Data are means± standard deviation or n (%).
BMI, body mass index; CAD, coronary artery disease; WHO, World Health Organization; ECG, electrocardiogram; TC, total cholesterol;
HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TG, triglyceride.
a Efﬁcacy cohort (n = 18,084).
b p < 0.01 (Fisher) for primary vs. secondary.
c p < 0.01 (Mann—Whitney) for primary vs. secondary.
t
a
a
≥
O
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e
ad p < 0.01 (Fisher) for ≥65 vs. <65 years old.
e p < 0.01 (Mann—Whitney) for ≥65 vs. <65 years old.
Table 1 shows the characteristics of the patients in the
otal cohort, the primary/secondary prevention cohorts and
ccording to age group (<65 vs. ≥65 years old). The mean
ge of the total cohort was 62.3± 11.1 years (8563 aged
65 years), and most of the patients were female (70.6%).
verall, 1222 (6.4%) had a history of cerebrovascular disor-
ers, 3056 (16.0%) had a history of cardiac disease, 3325
17.4%) had diabetes or impaired glucose tolerance, and
o
d
T
v855 (46.4%) had hypertension. Only 249 (1.3%) patients had
istory of treatment with lipid-lowering drugs. As would be
xpected, there were signiﬁcant differences between those
ged <65 and those aged ≥65 years old, particularly in terms
f the ‘classic’ risk factors, such as hypertension, cardiac
isease, cerebrovascular disorders, and ECG abnormalities.
he mean dose of ﬂuvastatin was comparable between pre-
ention cohorts and age groups.
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Table 2 Overall incidence of cardiac/cerebral events and mortality.
n patients at risk n patients affected Incidence (/1000 patients/year) 95% CI
All cerebral events
Total cohort 18,084 114 2.40 2.22—2.59
Primary prevention 16,905 80 1.81 1.59—2.03
Secondary prevention 1179 34 10.35 10.01—10.69
All cardiac events
Total cohort 18,084 238 4.98 4.85—5.11
Primary prevention 16,401 142 3.19 3.02—3.35
Secondary prevention 1683 96 29.20 29.00—29.41
Myocardial infarction
Total cohort 18,084 55 1.12 0.84—1.39
Primary prevention 16,401 29 0.61 0.23—0.99
Secondary prevention 1683 26 7.76 7.37—8.15
Angina pectoris
Total cohort 18,084 130 2.75 2.57—2.92
Primary prevention 16,401 77 1.74 1.52—1.97
Secondary prevention 1683 53 16.06 15.79—16.34
Mortality
Total cohort 18,084 243 4.67 4.54—4.81
Primary prevention 16,401 194 4.17 4.02—4.31
Secondary prevention 1683 49 11.39 11.07—11.71
Incidence (/1000 patients/year): [No. of patients with cardiac events (calculable cases)]/[(total no. of days on which the events
occurred)/365]× 1000; to calculate the incidence, patients for whom the time to event was not available were excluded; CI, conﬁdence
interval.
Table 3 Changes in lipid parameters.
Total Primary Secondary <65 years ≥65 years
LDL-C
Initial 172.5 173.1 166.6 174.1 170.5
Final 123.4 123.4 122.8 126.7 120.3
Change −49.1 −49.6 −43.7 −47.4 −50.2
% change −28.5 −28.7 −26.3 −27.2 −29.4
HDL-C
Initial 59.9 60.3 56.0 60.0 59.8
Final 60.5 61.1 56.3 61.1 59.9
Change 0.6 0.8 0.2 1.1 0.1
% change 1.0 1.4 0.4 1.9 0.1
TC
Initial 263.4 264.2 255.4 265.9 260.3
Final 210.7 211.3 207.0 215.6 206.1
Change −52.7 −52.9 −48.4 −50.3 −54.2
% change −20.0 −20.0 −18.9 −18.9 −20.8
TG
Initial 166.3 165.5 174.6 175.5 155.0
Final 138.4 136.8 149.7 145.2 131.9
; LDL
a
aChange −27.9 −28.8
% change −16.8 −17.4
TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol
Prevalence of cardiac and cerebral events in the
total cohort and in the primary and secondary
prevention cohorts
The EEC reviewed a total of 368 and 238 suspected cases
of cardiac and cerebral events, respectively. Of these, 275
a
(
t
c−24.8 −30.3 −23.1
−14.2 −17.3 −14.9
-C, low-density lipoprotein-cholesterol; TG, triglyceride.
nd 155 cases, respectively, were conﬁrmed by the EEC,
nd 238 and 114, respectively, were included in the efﬁcacy
nalysis set. Conﬁrmed cardiac events included unstable
n = 29), effort (n = 10), and ‘other’ angina (n = 152); asymp-
omatic (n = 61), non-fatal (n = 49), and fatal MI (n = 13), and
oronary spastic angina (n = 9). Conﬁrmed cerebral events
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Table 4 Incidence of cardiac and cerebral events according to prevention cohort and age group.
n patients n events Incidence (/1000 patients/year) 95% CI HRa p
Cardiac
Primary
<65 years old 9358 63 2.68 2.43—2.92
≥65 years old 7039 79 3.78 3.55—4.00 1.43 0.037
Secondary
<65 years old 621 42 35.55 35.23—35.86
≥65 years old 1062 54 25.72 25.45—25.99 0.67 0.059
Cerebral
Primary
<65 years old 9616 18 0.76 0.29—1.22
≥65 years old 7285 62 3.05 2.80—3.30 4.08 <0.0001
Secondary
<65 years old 363 10 9.67 9.04—10.30
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o≥65 years old 816 24 10.67
CI, conﬁdence interval; HR, hazard ratio.
a vs. <65 years old.
ncluded cerebral infarction (n = 114), TIA (n = 13), cerebral
emorrhage (n = 20), subarachnoid hemorrhage (n = 7), and
erebral venous thrombosis (n = 1).
umulative incidence of cerebral/cardiac events
nd death
he cumulative incidences of major events in the primary
nd secondary prevention cohorts were 1.48% and 7.28%,
espectively, for cardiac events, and 0.84% and 4.80%,
espectively, for cerebral events. Thus, the cumulative inci-
ences of cardiac and cerebral events in the secondary
revention cohort were 4.9- and 5.7-times higher, respec-
ively, than those in the primary prevention cohorts. The
umulative mortality rates in the primary and secondary
revention cohorts were 2.05% and 3.59%, respectively. The
ncidence of cardiac and cerebral events was 4.98 (95%
I: 4.85, 5.11) and 2.40 (95% CI: 2.22, 2.58) events/1000
atients/year, respectively, and was higher in the secondary
revention cohort than in the primary prevention cohort
Table 2). Similar trends were observed in terms of angina
ectoris and MI (Table 2).
ffects of ﬂuvastatin on lipid parameters in the
rimary and secondary cohorts
luvastatin elicited sustained reductions in both LDL-C and
C by 28.7% and 20.0%, respectively, in the primary preven-
ion cohort, and by 26.3% and 18.9%, respectively, in the
econdary prevention cohort (Table 3). Meanwhile, HDL-C
ncreased by 1.4% and 0.4%, respectively, and TG decreased
y 17.4% and 14.2%, respectively.
ffects of long-term ﬂuvastatin on the incidence of
ardiac and cerebral events and lipid levels in
atients aged ≥65 years old
s shown in Table 4, the incidences of cardiac and cerebral
vents in the primary cohort were higher in those aged ≥65
s
M
c
(
(10.26—11.07 1.33 0.546
ears old than in those aged <65 years old. By contrast, in the
econdary cohort, the incidence of cardiac events was higher
n patients aged <65 years old. There was little difference in
he rate of cerebral events. This suggests that older patients
ithout a history of an event are at increased risk of future
vents compared with younger patients without history of
n event. Furthermore, among patients with a history of an
vent, the risk of future cardiac events seems to be higher
mong younger patients, while there is no difference in the
isk of cerebral events. As shown in Fig. 1, these overall
atterns were maintained throughout the study.
Fluvastatin exerted sustained reductions in LDL-C and
C in both age groups of patients (Fig. 2). Interest-
ngly, the magnitudes of changes in LDL-C (−47.4 vs.
50.2mg/dL [−27.2 vs. −29.4%], p = 0.002) and TC (−50.3
s. −54.2mg/dL [−18.9 vs. −20.8%], p < 0.0001) were signif-
cantly greater among patients aged ≥65 years old compared
ith those aged <65 years old (Table 3).
ssociations between risk factors with cardiac and
erebral events
ecause cardiovascular and cerebral events are strongly
ssociated with a multitude of risk factors, including LDL-
levels, we also analyzed the association between these
isk factors at baseline with the incidence of events using
he Cox proportional hazards model (Supplementary Fig.
). Overall, 12 baseline factors were signiﬁcant in the pri-
ary prevention group (Supplementary Fig. 2A), including
ex, age in men (≥65 years), age group (55—60 and 70—75
ears), obesity (BMI ≥25 kg/m2 and diabetes), and compli-
ations (hypertension, diabetes, hypertension and diabetes,
ardiac disease, cerebral disease, cerebral infarction, and
trial ﬁbrillation). Five factors were signiﬁcant in the sec-
ndary prevention group, namely menopause in women, sex,
moking, TG ≥150mg/dL, and complications (diabetes).
eanwhile, 14 factors were signiﬁcantly associated with
erebral events in the cerebral primary prevention cohort
Supplementary Fig. 2B). These included age in women
≥55 and ≥65 years), age in men (≥65 years), age group
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Figure 1 Kaplan—Meier survival curves for cardiac (A, B) and cerebral (C, D) events in the primary (A, C) and secondary (B, D)
prevention cohorts in patients aged <65 vs. ≥65 years old. The incidence of cardiac and cerebral events was estimated using the
oups.
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tKaplan—Meier method followed by log-rank tests to compare gr
higher among patients aged ≥65 years old within the secondary
the primary prevention cohort.
(55—60, 70—75, 75—80, and ≥80 years old), smoking, TG
≥150mg/dL, and complications (hypertension and diabetes,
cardiac disease, kidney disease, and atrial ﬁbrillation). In
the cerebral secondary prevention cohort, the following fac-
tors were signiﬁcant: age group (55—60, 70—75, 75—80, and
≥80 years), obesity (BMI ≥25 kg/m2 and diabetes), and com-
plications (diabetes, cardiac disease, and atrial ﬁbrillation).
Relative risk of cardiac events according to lipid
levels
Fig. 3 shows the relative risk of cardiac events in the primary
and secondary cohorts according to classes of LDL-C, TC, and
HDL-C. As would be expected, in terms of LDL-C, the risk
of cardiac events was the highest for patients with LDL-C
≥180mg/dL (Fig. 3A and B) or with HDL-C <40mg/dL (Fig. 3C
and D) in both the primary and secondary cohorts. In terms of
TC, the proﬁles showed a more complex relationship. In the
primary prevention cohort, the risks were markedly elevated
in patients with TC <180mg/dL or ≥260mg/dL (Fig. 3E). By
contrast, in the secondary cohort, the risks were greater in
a
o
a
7
eThe incidence of cardiac and cerebral events was numerically
ntion cohort compared with patients aged <65 years old within
atients with TC ≥260mg/dL (Fig. 3F), but were actually
ower than those in the reference category in the other sub-
roups.
dverse events
he incidence of adverse events was 7.9% (1501/19,084)
n the total cohort. In terms of adverse drug reactions
Table 5), the most common events included increased blood
K in 140 patients (0.7%), abnormal liver function in 126
atients (0.7%), muscle pain in 88 patients (0.5%), nau-
ea in 78 patients (0.4%), and stomach discomfort in 68
atients (0.4%). Considering the side effects described in
he package insert, there were no adverse drug reactions
hat have not already been described for ﬂuvastatin and
here were no conﬁrmed episodes of rhabdomyolysis. Over-
ll, there was a small, non-signiﬁcant difference in the rate
f adverse events between patients aged ≥65 and those
ged <65 years old (n = 792/10,517 vs. 709/8563 [8.3% vs.
.5%], p = 0.058). Furthermore, the prevalence of adverse
vents was not dose-dependent, as the prevalence was
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Figure 2 Effects of ﬂuvastatin on the time-course of changes in LDL-C (A, B), TC (C, D) in the primary (A, C) and secondary (B, D)
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erevention cohorts in patients aged <65 years vs. those aged ≥
n both age groups of patients. p-Values were calculated for pat
ears; secondary prevention cohort, 3 years). LDL-C, low-densi
ot signiﬁcantly different (p = 0.65) among patients taking
20mg/day (1763 events in 1320/16,706 [7.9%] patients),
0mg/day (147 events in 188/1917 [7.7%] patients), or
40mg/day (34 events in 48/461 [7.4%] patients).
iscussion
ased on their extensive clinical history, dating back over
0 years, statins are now widely used for the treatment of
ypercholesterolemia, and have been shown to signiﬁcantly
educe the incidence of cardiovascular disease and death.
In the present study, ﬂuvastatin elicited sustained reduc-
ions in both LDL-C and TC in the primary and secondary
revention cohorts of Japanese patients. Interestingly, these
eductions in lipid parameters tended to be greater over
ime among patients aged ≥65 years old than in those aged
65 years (Fig. 2 and Table 3). However, the magnitude of
he differences between these groups of patients was small
nd may not be clinically relevant in terms of risk proﬁles.
hese results are broadly consistent with those of other simi-
arly designed studies in Japanese patients, such as the J-LIT
tudy of 51,321 patients treated with simvastatin, in which
a
c
p
p
Sars. Fluvastatin exerted sustained reductions in LDL-C and TC
with data at the ﬁnal follow-up (primary prevention cohort, 5
oprotein cholesterol; TC, total cholesterol.
DL-C and TC were reduced by 26.0% and 18.3%, respec-
ively, in the total study population [9].
As expected, the incidence of cardiac and cerebral events
as slightly higher in the secondary prevention cohort than
hat in the primary prevention cohort (Table 2). Clearly, the
econdary prevention cohort should be a major target for
ntervention. Many studies have already demonstrated that
ipid-lowering therapy shows marked risk reduction on such
vents in high-risk primary [10—12] and secondary [13—16]
revention cohorts. Although we did not include a control
r comparator group in this study, ﬂuvastatin therapy for
p to 5 years (3 years in the secondary prevention cohort)
as associated with a low incidence of cardiac and cerebral
vents, such as MI and cerebral infarction, which was con-
istent with ﬁndings of other, shorter-term studies in Japan
nd worldwide [1,3,9,17,18].
As many patients with hypercholesterolemia are consid-
red elderly (≥65 years old), we performed a sub-analysis
ccording to age, <65 vs. ≥65 years old. The incidence of
ardiac and cerebral events was signiﬁcantly higher among
atients aged ≥65 years than those aged <65 years in the
rimary cohort, but not in the secondary prevention cohort.
urprisingly, in the secondary prevention cohort, the inci-
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ed ba
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t
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<Figure 3 Relative risk of cardiac events according to LDL-C
and secondary (B, D, F) cohorts. The reference group was deﬁn
Society. HDL-C, high-density lipoprotein cholesterol; LDL-C, low
dence of cardiac events was higher among patients aged
<65 years than in those aged ≥65 years. This population
represents a very high-risk patient population with marked
predisposition to future events, namely high incidence of
hypertension, diabetes, and ECG irregularities. In fact,
improvements in LDL-C and TC were signiﬁcantly greater in
patients aged ≥65 years old than in those aged <65 years old,
although the clinical relevance of the difference between
these groups remains to be established. To our knowledge,
this is the ﬁrst such study to determine the efﬁcacy of ﬂu-
m
o
g
g
h), HDL-C (C, D) and TC (E, F) classes in the primary (A, C, E)
sed on the target level proposed by the Japan Atherosclerosis
sity lipoprotein cholesterol; TC, total cholesterol.
astatin in elderly patients in Japan. These ﬁndings support
he previous ﬁndings of a short-term prospective double-
lind study [19] and those of a pooled analysis [20] of 30
linical trials in predominantly white patients (∼96%), aged
65 vs. ≥65 years old. Although it is unclear why improve-
ents in LDL-C and TC were greater in those aged ≥65 years
ld, this may reﬂect more intensive lipid-lowering, blood
lucose-lowering, and antihypertensive therapies to provide
lobal health beneﬁts, particularly among those with a prior
istory of events (i.e. in the secondary prevention cohort).
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Table 5 Adverse drug reactions in ≥0.01% of patients.
Adverse drug reactions total ≥65 years old <65 years old
n % n % n %
Disorder of nervous system
Dizziness 29 0.2 15 0.2 14 0.1
Headache 20 0.1 8 0.1 12 0.1
Hypoesthesia 28 0.2 15 0.2 13 0.1
GI disorder
Upper abdominal pain 29 0.2 10 0.1 19 0.2
Constipation 34 0.2 21 0.3 13 0.1
Diarrhea 22 0.1 13 0.2 9 0.1
Dyspepsia 22 0.1 11 0.1 11 0.1
Gastritis 22 0.1 13 0.2 9 0.1
Nausea 78 0.4 35 0.4 43 0.4
Gastric discomfort 68 0.4 37 0.4 31 0.3
Disorder of the hepatobiliary system
Hepatic dysfunction 126 0.7 43 0.5 83 0.8
Dermis
Pruritus 34 0.2 19 0.2 15 0.1
Rash 36 0.2 15 0.2 21 0.2
Musculoskeletal system
Muscle spasm 28 0.2 13 0.2 15 0.1
Muscle pain 88 0.5 34 0.4 54 0.5
Systemic disorder
Fatigue 31 0.2 13 0.2 18 0.2
Laboratory test abnormal
ALT 68 0.4 20 0.2 48 0.5
AST 61 0.3 19 0.2 42 0.4
5
1
K, c
B
r
s
t
b
C
o
i
e
L
t
T
b
o
t
c
e
i
e
l
p
t
e
a
[
i
[
a
g
g
t
t
d
S
c
n
c
o
v
t
t
o
i
H
o
eCK 140 0.7
-GTP 51 0.3
ALT, alanine aminotransferase; AST, aspartate aminotransferase; C
y contrast, patients aged <65 years old with fewer ‘classic’
isk factors may receive less intensive intervention.
In terms of the direct effects of lipid-lowering therapy, a
ub-analysis of the 4S study [21] revealed a curvilinear rela-
ionship in the relative risk (RR) between post-treatment
lood serum LDL-C levels and CAD events (fatal and non-fatal
AD and sudden cardiac death). Meanwhile, a sub-analysis
f the CARE study [22] showed a threshold relationship
n the RR between LDL-C levels and recurrent coronary
vents, as the event rate decreased with reductions in
DL-C from 174mg/dL to 125mg/dL, but no further reduc-
ion occurred with further decreases in LDL-C to 71mg/dL.
hus, it remains unclear whether further reductions in LDL-C
elow 125mg/dL provide further reductions in the incidence
f coronary events.
While the reduction in cardiovascular events by statin-
ype drugs is mainly thought to be due to their
holesterol-lowering effects, statins have been shown to
xert many other beneﬁcial effects including improvements
n vascular endothelial function [23], anti-inﬂammatory
ffects, antioxidant effects [24,25], smooth muscle cell pro-
iferation [26], and enhanced stability of atherosclerotic
laques [27]. Abe et al. previously reported that ﬂuvas-
atin, but not simvastatin, increased eNOS mRNA levels by
nhancing the transcriptional activities of the eNOS gene
nd mRNA stability in human umbilical vein endothelial cells
28]. Therefore, lipid-independent effects may play a role
C
l
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d2 0.6 88 0.8
9 0.2 32 0.3
reatine kinase; -GTP, -glutamyl tranferase.
n the moderate LDL-C reduction achieved with ﬂuvastatin
29].
As shown in Fig. 3, the relative risk for cardiac events
ccording to mean LDL-C levels in the primary prevention
roup was signiﬁcantly greatest at LDL-C ≥180mg/dL, sug-
esting that ﬂuvastatin acts as a vascular statin and reduces
he risk of events in patients with LDL-C <180mg/dL. Indeed,
he ability of ﬂuvastatin to protect vascular walls has been
emonstrated in the SCAST (Statin and Coronary Artery
pasm Trial) [30], in which ﬂuvastatin in combination with
onventional calcium channel blocker (CCB) therapy sig-
iﬁcantly suppressed the occurrence of vasospastic angina
ompared with CCB therapy alone. Of note, the prevalence
f vasospastic angina is markedly higher in Japanese indi-
iduals than in Westerners. Thus, interventions that reduce
he risk of such cardiac events should be considered in
he multifactorial treatment of high-risk patients. In sec-
ndary prevention settings, the risk of cardiovascular events
s signiﬁcantly lower in patients with LDL-C <100mg/dL.
owever, the required level of control to reduce the risk
f events is less clear in primary prevention settings. For
xample, a sub-analysis of the results of the West of Scotland
oronary Prevention Study [2] showed that the cardiovascu-
ar event prevention effect does not increase, even when
DL-C decreased by ≥24%. Similarly, the J-LIT study [9] in
apanese patients revealed a plateau in the risk of coronary
isease in patients with LDL-C <160mg/dL. In our study, the
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risk of cardiovascular events reached a plateau at an LDL-
C level of <180mg/dL. Clearly, further studies are needed
to ascertain the meaning of these ﬁndings and to provide
clinical guidance on targets for primary prevention.
Overall, adverse events were reported in 1501 patients
(7.9%) in the total cohort. The most common events included
elevated blood CK, abnormal liver function, muscle pain,
nausea, and stomach discomfort, which is consistent with
the package insert, and no new events were reported in
this study, conﬁrming the tolerability of ﬂuvastatin in every-
day clinical use. Although some patients reported muscle
pain or elevated blood CK levels, none of these cases was
found to be rhabdomyolysis, an adverse event that has
gained increasing attention in patients treated with statins
[31—33]. Nevertheless, appropriate assessment of muscle
pain and measurement of blood CK levels can help the clin-
ician to determine the possible risk of rhabdomyolysis and
related events, and encourage changes in statin dosage or
consider changes to the treatment regimen if deemed nec-
essary [34]. Nevertheless, the incidence of such events in
this long-term study was low and any changes to therapy
should take into account the advantages of statin therapy
on risk reduction for major cardiac and cerebral events
[35].
Finally, the results of this study should be interpreted
with care, taking into account the limitations of this study.
First, this was an open-label, non-randomized, uncontrolled
study without a comparator group. Second, the study was
limited to Japanese patients who were selected for reg-
istration in this study by their physician. Thus, some bias
may exist as the physicians may have selected their ‘least
severe’ patients. However, this is unlikely, as a large number
of patients were identiﬁed after registration for inclusion in
a secondary prevention cohort, and the characteristics of
the patients in this group suggest moderate to high risk for
future events. Finally, the results may not be generalizable
to other countries.
Conclusions
In conclusion, the results of this long-term cohort study con-
ﬁrm the efﬁcacy and tolerability of ﬂuvastatin in Japanese
patients with or without prior history of cardiac or cerebral
events. Furthermore, this analysis also revealed a low risk of
events in patients aged ≥65 years old with or without prior
history of cardiac or cerebral events, patient populations
that are increasingly being encountered in everyday clinical
practice. Finally, we found that long-term therapy with ﬂu-
vastatin elicited signiﬁcantly greater improvements in lipid
control, particularly of LDL-C and TC, in patients aged ≥65
years than in patients aged <65 years, among those that per-
sisted throughout the study. However, the magnitude of this
difference is small and the clinical relevance remains to be
established.Disclosure
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